

## **Corso di Dottorato di Ricerca in Scienze della Vita e** dell'Ambiente - Ciclo XXXVI **Novel 13-Berberine derivatives compounds as Efflux** pump inhibitors against MexY variants of Pseudomonas aeruginosa PhD Student: Giorgia Giorgini Tutor: Prof.ssa Galeazzi Roberta **Molecular Modeling and Drug Design Lab**

For this project, we started with Berberine, a natural alkaloid that is capable of tightly binding to the MexY protein of the EP (Efflux Pump) system MexXY-OprM in Pseudomonas aeruginosa. The mechanism of action of Berberine was elucidated using computational techniques and in vitro microbiological assays



To increase the activity and binding specificity of the EPI (Efflux Pump Inhibitor), we synthesized berberine derivatives functionalized at the C-13 position. The binding modes of these derivatives were investigated using computational techniques.



By in vitro checkerboard assays, we assessed their inhibitory activity when used in synergy with the aminoglycoside Tobramycin, mostly extruded by this EP in MDR P. aeruginosa resistant strains.



The three conformations: loose (L), tight(T) and open(O) were used for the blind docking and molecular dynamics simulation, to assess the Berberine repositioning and its binding affinity. Molecular interaction on the Tight and free gibbs binding energy calculated are depicted in the table below

	Loose	Tight DBP	Tight Accessory	Open
Berb	-7,70kcal/mol	-6,97 Kcal/mol	-8,66kcal/mol	-6,32kcal/mol
Tob.	-9,62kcal/mol	-5,96kcal/mol	/	-5.54kcal/mol







Tobramycin within the deep binding pocket interacts with residues shown. On the left there's the homotrimeric complex system with the main pockets inside the porter domain



Molecular docking: autodock 2.4.6 with AMBER forcefield based scoring function. GA algorithm 100 runs Molecular dynamics: GROMAC202.6, CHARMM36m, 100ns production run; PBC conditions; POPC bilayer system; TIP3P water model; NaCl 0,15M **MM/PBSA** last ns of MD simulation after stabilization



After the molecular dynamic simulation, the positioning of Berberine in each pocket within all the monomer states was compared. The free Gibbs binding energy was calculated **Results: :** Berberine demonstrates the ability to tightly bind to the T monomer in a competitive manner, similar to Tobramycin. This was confirmed through the calculation of free binding energy using MM/PBSA. Additionally, from the docking analysis, another site known as the non-competitive site exhibited the highest binding affinity energy (-8.66 kcal/mol) compared to other pockets. For this reason, another molecular dynamics simulation was conducted to compare the positioning of Berberine in the homotrimeric tight system within both the competitive and non-

## **Chemical synthesis:**

Berberine reduction to Dihydroberberine (1equiv), with KI (2equiv) in CH<sub>3</sub>CN 40mL solution added to benzylbromide substituent. Solution refluxed under stirring for 4h, the extract has been purified with  $CHCl_3/CH_3OH$  (50:1) as eluent.



Docking and Molecular Dynamics simulations were conducted within MexY of the highly resistant strain PA7, and the results were analyzed. Docking analysis of all these compounds was also performed in other forms of MexY, particularly in proteins from





MET

After the MD simulation, it can be observed that Berberine within the non-competitive pocket is more stabilized by hydrogen bond and  $\pi$ -alkyl interactions, whereas within the deep binding pocket it is only stabilized in its benzodioxazolic moiety

The MM/PBSA calculations also indicate that Berberine within the non-competitive site (-501 kJ/mol) exhibits better stability compared to the competitive site (-444 kJ/mol).





Checkerboard assays: were performed using 2-fold dilutions of tobramycin from 0 to 520  $\mu$ g/ml and berberine derivatives from 10 to 160 µg/ml, preliminarily proven to be devoid of antibacterial activity.

## **3.**Conclusion

The 13(2-methylbenzyl)berberine has its best activity compared to the 13benzylberberine, both against resistant and susceptible cells. Regarding the 13(4-nitrobenzyl)berberine, there's a reduced or no activity in all strains, probably due to the increasing polarity in the functionalizing group.

- Are ongoing studies for the possibility of the encapsualtion of this